Why Is BRISTOL MYERS SQUIBB (BMY) Stock Moving Today?

BMY stock is moving 0.27% higher in afternoon trading after a volatile session that saw the stock briefly touch a 52-week high. The stock opened at $60.62 and climbed to $62.29 before retreating to $60.79 in the last print. The move comes amid a backdrop of recent regulatory and partnership developments for Bristol Myers Squibb, including FDA acceptance of a new multiple myeloma treatment application and a companion diagnostic approval for its PD-L1 assay.

What Happened

BMY’s stock has been lifted by a combination of regulatory and market factors. The FDA accepted the New Drug Application for Mezigdomide in combination with Carfilzomib and Dexamethasone for relapsed or refractory multiple myeloma, with a PDUFA date set for May 13, 2027. This development is seen as a step toward expanding the company’s oncology portfolio. Additionally, Agilent received FDA approval for a companion diagnostic for BMY’s OPDIVO, potentially broadening patient eligibility for the drug. On the market side, the stock’s intraday performance reflects strong early buying pressure, with volume at 10.4 million shares, or 90% above its 3-month average. The stock also hit a fresh 52-week high on July 17, indicating renewed investor interest.

What The Data Shows

The stock’s recent price trend has been mixed, with an 8-session decline of 3.5% from $58.03 to $55.98. However, the latest session saw a reversal, with the stock closing near the upper end of its range. Options activity has also been skewed toward calls, with $1.4 million in call premiums traded versus $0 in puts. The stock’s fundamentals remain strong, with a 4.42% dividend yield and a P/E ratio of 16.9, while its beta of 0.24 suggests low volatility relative to the broader market.

What To Watch

Investors should monitor the May 2027 PDUFA date for Mezigdomide and the broader coverage landscape as BMY approaches its next earnings report. Analysts from B of A Securities and Cantor Fitzgerald have maintained Buy and Neutral ratings, respectively, with price targets of $66 and $54.